Suven gets five product patents for NCEs
Published on April 24, 2015 13:43:07 PM
Suven Life Sciences has received one product patent each from Australia, Europe, Hong Kong, Israel, Norway for the New Chemical Entities (NCEs) used to treat Neurodegenerative diseases.
These class of selective 5-HT compounds by Suven are developed as therapeutic agents, which are used to treat cognitive impairment associated with neurodegenerative disorders like Huntington’s disease, Schizophrenia , Attention deficient hyperactivity disorder (ADHD), Alzheimer’s disease and Parkinson.
With these new patents, Suven has total granted patents of 21 from Australia, 15 from Europe, 16 Hong Kong, 4 from Israel and 5 from Norway.